Documentos
SML0586
Lomeguatrib
≥98% (HPLC)
Sinónimos:
O6-(4-bromothenyl)guanine, 2-Amino-6-[(4-bromo-2-thienyl)methoxy]-9H-purine
Empirical Formula (Hill Notation):
C10H8BrN5OS
Número de CAS:
Peso molecular:
326.17
MDL number:
PubChem Substance ID:
NACRES:
NA.77
En este momento no podemos mostrarle ni los precios ni la disponibilidad
Quality Level
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 10 mg/mL, clear
storage temp.
room temp
SMILES string
Nc1nc(OCc2cc(Br)cs2)c3nc[nH]c3n1
InChI
1S/C10H8BrN5OS/c11-5-1-6(18-3-5)2-17-9-7-8(14-4-13-7)15-10(12)16-9/h1,3-4H,2H2,(H3,12,13,14,15,16)
InChI key
JUJPKFNFCWJBCX-UHFFFAOYSA-N
Packaging
5, 25 mg in glass bottle
Biochem/physiol Actions
Lomeguatrib is a highly potent inactivator of O(6)-methylguanine-DNA methyltransferase (MGMT), a DNA repair protein which can confer resistance to some cancer chemotherapeutics, in particular the DNA alkylating agents such as Temozolomide, DTIC, Carmustine, etc. Lomeguatrib is a highly potent inactivator of MGMT and can be used to further investigate mechanisms of resistance. It is a potent irreversible inactivator of all mammalian O6-alkylguanine-DNA-alkyltransferases, so far tested with nanomolar activity in vitro and in vivo.
Features and Benefits
This compound is also offered as part of Sigma′s Library of Pharmacologically Active Compounds (LOPAC®1280), a biologically annotated collection of high-quality, ready-to-screen compounds. Click here to learn more.
Legal Information
LOPAC is a registered trademark of Sigma-Aldrich Co. LLC
Certificado de Análisis
Certificado de origen
Más documentos
A Sabharwal et al.
Cancer chemotherapy and pharmacology, 66(5), 829-835 (2009-12-30)
Expression of the DNA repair protein O (6)-methylguanine-DNA methyltransferase (MGMT) correlates with resistance to irinotecan in colorectal cancer cell lines. This phase I study evaluated the maximum tolerated dose (MTD) of lomeguatrib, an inactivating pseudosubstrate of MGMT, in combination with...
Malcolm Ranson et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25(18), 2540-2545 (2007-06-20)
To evaluate tumor response, pharmacodynamic effects, and safety of a combination of lomeguatrib (LM), an O6-methylguanine DNA-methyltransferase (MGMT) inactivator, and temozolomide (TMZ), TMZ alone, and LM/TMZ after disease progression on TMZ alone in patients with advanced melanoma. Patients with unresectable...
T Brian H McMurry
DNA repair, 6(8), 1161-1169 (2007-05-09)
The DNA repair protein, O(6)-alkylguanine-DNA alkyltransferase (MGMT) can confer resistance to the cancer chemotherapeutic effects of the class of DNA damaging drugs generally referred to as the O(6)-alkylating agents. Inactivation of MGMT is thus a practical approach to improving the...
[Analysis of the relevant factors of mechanism for telozolomide chemoresistance].
Zeng-feng Sun et al.
Zhonghua zhong liu za zhi [Chinese journal of oncology], 33(10), 794-796 (2012-02-18)
Patrizia Caporaso et al.
DNA repair, 6(8), 1179-1186 (2007-05-15)
Previous studies indicated that dacarbazine and Temozolomide could be highly effective against refractory acute leukaemia. Their activity relies mainly on the generation of methyl adducts at the O(6)-position of guanine in DNA. High levels of O(6)-methylguanine-DNA methyltransferase (MGMT) or a...
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnicoAsistencia técnica
Servicio de atención al clienteContacte con nosotrosPreguntas frecuentesFichas técnicas de seguridad (SDS)Certificados (COA y COO)Calidad y registrosCalculadoras y aplicacionesSeminarios virtualesRedes sociales
Merck
Investigación. Desarrollo. Producción.
Somos un proveedor líder para la industria de Ciencias de la Vida con soluciones y servicios para investigación, desarrollo y producción biotecnológicos, y para desarrollo y producción de tratamientos farmacéuticos
Sigma-Aldrich®Soluciones BioReliance®Soluciones Millipore®Soluciones SAFC®Soluciones
Milli-Q®Soluciones Supelco®
© 2021 Merck KGaA, Darmstadt, Alemania y/o sus filiales. Todos los derechos reservados.
Queda estrictamente prohibida la reproducción sin permiso de cualquiera de los materiales de la página web.